An evidence-based approach to the management of pulmonary arterial hypertension.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current Opinion in Cardiology

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.HCO.0000240592.44957.4BPMID 16900019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

  2006cited by this paper
• An evidence-based approach to the management of pulmonary arterial hypertension.

  2006cited by this paper
• Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

  2005cited by this paper
• Ambrisentan for pulmonary arterial hypertension.

  2005cited by this paper
• Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

  2002cited by this paper

• Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis

  2017cites this paper
• Carfilzomib reverses pulmonary arterial hypertension.

  2016cites this paper
• Quantification of Coupled Stiffness and Fiber Orientation Remodeling in Hypertensive Rat Right-Ventricular Myocardium Using 3D Ultrasound Speckle Tracking with Biaxial Testing

  2016cites this paper
• Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension

  2015cites this paper
• Absence of the calcium-binding protein, S100A1, confers pulmonary hypertension in mice associated with endothelial dysfunction and apoptosis.

  2015cites this paper
• Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension The PHACeT Trial

  2015cites this paper
• YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels

  2015cites this paper
• Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

  2015cites this paper
• Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension The PHACeT Trial

  2015cites this paper
• What is good for the circulation also lessens cancer risk.

  2015cites this paper
• Mechanism of the Susceptibility of Remodeled Pulmonary Vessels to Drug‐Induced Cell Killing

  2014cites this paper
• The Genetics of Pulmonary Arterial Hypertension

  2014cites this paper
• The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases

  2014cites this paper
• Pulmonary Arterial Hypertension: Challenges in Translational Research and a Vision for Change

  2013cites this paper
• A Comparison of Pattern of Breathing during Incremental Exercise in Patients with Pulmonary Fibrosis and Primary Pulmonary Hypertension

  2013cites this paper
• Dihydropyridine Ca 2+ Channel Blockers Increase Cytosolic [Ca 2+ ] by Activating Ca 2+ -sensing Receptors in Pulmonary Arterial Smooth Muscle Cells

  2013cites this paper
• Heritable Forms of Pulmonary Arterial Hypertension

  2013cites this paper
• Dihydropyridine Ca 2+ Channel Blockers Increase Cytosolic [Ca 2+ ] by Activating Ca 2+ -sensing Receptors in Pulmonary Arterial Smooth Muscle Cells

  2013cites this paper
• Dihydropyridine Ca2+ Channel Blockers Increase Cytosolic [Ca2+] by Activating Ca2+-sensing Receptors in Pulmonary Arterial Smooth Muscle Cells

  2013cites this paper
• Novel strategies for the management of right ventricular failure with pulmonary hypertension

  2012cites this paper
• Activation of JNK/c-Jun is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial cells[S]

  2012cites this paper
• Enhancer of Zeste Homolog 2 Induces Pulmonary Artery Smooth Muscle Cell Proliferation

  2012cites this paper
• Surgical treatment of pulmonary hypertension: Lung transplantation

  2011cites this paper
• Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension.

  2011cites this paper
• Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs.

  2011cites this paper
• Pulmonary arterial hypertension and statins: an update

  2011cites this paper
• Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension.

  2010cites this paper
• Genetics of Pulmonary Arterial Hypertension

  2009cites this paper
• Current practices in the use of sildenafil for pulmonary arterial hypertension in Brazilian hospitals

  2009cites this paper
• RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension

  2009influential citation
• Simvastatin and sildenafil combine to attenuate pulmonary hypertension

  2009cites this paper
• Pulmonary Arterial Hypertension in Systemic Sclerosis: Can We Predict Responders for Successful Therapy?

  2009cites this paper
• Exercise Training in Patients with Pulmonary Arterial Hypertension: A Case Report

  2009cites this paper
• The Role of Statins in Respiratory Diseases

  2009cites this paper
• Expert opinion on tilarginine in the treatment of shock

  2008cites this paper
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

  2008cites this paper
• Emerging concepts and translational priorities in pulmonary arterial hypertension.

  2008cites this paper
• Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.

  2007cites this paper
• Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

  2007cites this paper
• Pulmonary arterial hypertension and myeloproliferative disorders

  2007influential citation
• Genetics and mediators in pulmonary arterial hypertension.

  2007cites this paper
• Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility Heart Failure

  2007cites this paper
• How valid are animal models to evaluate treatments for pulmonary hypertension?

  2006cites this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Rhoa/rho-kinase Signaling: a Therapeutic Target in Pulmonary Hypertension Animal Models of Pulmonary Hypertension

  year unknowncites this paper